Arrhythmogenic Activity During Exercise in ARVC Patients

Inclusion Criteria

• •Definitive ARVC diagnosis according to the modified 2010 ARVC Task Force Criteria
• •Pathogenic / likely pathogenic variant in one of the following desmosomal genes: plakophilin-2 (PKP-2), desmoglein-2 (DSG-2) or desmoplakin (DSP) or gene-elusive definite ARVC (i.e., genetic test performed but no pathogenic / likely pathogenic variant found)
• •Control group: diagnosed ischemic heart disease with ejection fraction above 35%
• •Agreement with responsible primary cardiologist that study participation is not considered beyond acceptable levels of physical activity for this particular patient
• •No history of exercise-induced syncope in the 6 months prior to study participation
• •No history of sudden cardiac arrest in the 6 months prior to study participation
• •In patients who suffered from sudden cardiac arrest/arrhythmic syncope, only those having an implantable cardioverter-defibrillator (ICD) and being under beta-blockers/antiarrhythmic drugs are eligible for study inclusion
• •Informed Consent as documented by signature (Appendix Informed Consent Form)
• •Age: \> 14 years
• •Body-Mass-Index (BMI): 18.5 - 39.9 kg･m-2
• •Willing to adhere to the following study rules:
• •* No intense exercise 48h prior to testing
• •* No exercise 24h prior to testing
• •* Sleep at least 7h the two nights before testing On test day
• •* No caffeinated food or drink before testing on test day
• •* No alcohol before testing on test day
• •* Fully compliant with normal medication regimen including beta-blockers and antiarrhythmic medication